Quoin director granted options on 8,141 ADSs

Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant.

Rhea-AI Filing Summary

Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant. On February 4, 2026, he was awarded a Share Option (Right to Buy) covering 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals, Ltd. at an exercise price of $7.37 per ADS.

Each ADS represents thirty-five ordinary shares of the company. The option vests over four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Sember holds 8,141 derivative securities directly.

Insider Trade Summary

Grant/Award: 8,141 shares

Grant/Award 1 txn

Insider SEMBER MICHAEL T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	8,141	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 8,141 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quoin Pharmaceuticals (QNRX) report for Michael T. Sember?

Quoin Pharmaceuticals reported that director Michael T. Sember received a Share Option (Right to Buy) for 8,141 ADSs on February 4, 2026. This option grant is reflected as a derivative security held directly after the transaction.

How many Quoin Pharmaceuticals (QNRX) ADSs are covered by Michael Sember’s new option?

The new option held by Michael T. Sember covers 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals. According to the disclosure, he beneficially owns 8,141 derivative securities following the reported transaction, all in the form of this option grant.

What is the exercise price of Michael Sember’s Quoin Pharmaceuticals (QNRX) option?

The exercise price of Michael T. Sember’s Share Option in Quoin Pharmaceuticals is $7.37 per ADS. The filing notes that both the number of securities and the exercise price are stated in ADS terms, with each ADS representing thirty-five ordinary shares.

How do Quoin Pharmaceuticals (QNRX) ADSs relate to ordinary shares in this Form 4?

The Form 4 explains that the option terms are in American Depositary Shares (ADSs), and each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. This ratio applies to both the number of underlying securities and the stated exercise price of the option grant.

What is the vesting schedule for Michael Sember’s Quoin Pharmaceuticals (QNRX) stock option?

The option vests in four annual installments. 20% vests on each of February 4, 2027, February 4, 2028 and February 4, 2029, with the remaining 40% vesting on February 4, 2030, as described in the filing footnote.

When does Michael Sember’s Quoin Pharmaceuticals (QNRX) option expire?

The disclosed Share Option for Michael T. Sember has an expiration date of February 4, 2036. The transaction table lists February 4, 2036 as the expiration, with the option becoming exercisable according to its multi-year vesting schedule outlined in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEMBER MICHAEL T

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		8,141(1)		(2)	02/04/2036	ADS	8,141(1)	$0	8,141(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Michael Sember	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.